

SUPPORTING INFORMATION

**New-synthesised oxime and lactone derivatives from *Dipterocarpus alatus* dipterocarpol as anti-diabetic inhibitors:  
experimental bioassay-based evidence and theoretical computation-based prediction**

**Tran Thi Phuong Thao<sup>1,2§</sup>, Thanh Q. Bui<sup>3§</sup>, Nguyen Thi Thanh Hai<sup>3</sup>, Lam K. Huynh<sup>4</sup>, Phan Tu Quy<sup>5</sup>, Nguyen Chi Bao<sup>6</sup>, Nguyen Thi Dung<sup>1</sup>,  
Nguyen Linh Chi<sup>1,2</sup>, Tran Van Loc<sup>1,2</sup>, Irina E. Smirnova<sup>7</sup>, Anastasiya V. Petrova<sup>7</sup>, Pham Thi Ninh<sup>1,2</sup>, Tran Van Sung<sup>1,2\*</sup>, Nguyen Thi Ai Nhungh<sup>3\*</sup>**

<sup>1</sup>Institute of Chemistry, Vietnam Academy of Science and Technology (VAST), 18 Hoang Quoc Viet Road, Cau Giay, Ha Noi, Vietnam.

<sup>2</sup>Graduate University of Science and Technology, VAST, 18 Hoang Quoc Viet Road, Cau Giay, Ha Noi, Vietnam.

<sup>3</sup>Department of Chemistry, University of Sciences, Hue University, Hue City, Vietnam.

<sup>4</sup>International University, Quarter 6, Linh Trung Ward, Thu Duc District, Ho Chi Minh City, Vietnam.

<sup>5</sup>Department of Natural Sciences & Technology, Tay Nguyen University, Buon Ma Thuot, Vietnam.

<sup>6</sup>Hue University, Hue City, Vietnam.

<sup>7</sup>Ufa Institute of Chemistry-Subdivision of the Ufa Federal Research Centre of the Russian Academy of Sciences, Ufa, prospekt Oktyabrya 71, Russian Federation.

<sup>§</sup>These authors contributed equally to this work.

\*Correspondence to:


Tran Van Sung (E-mail: travansungvh@gmail.com)


Nguyen Thi Ai Nhungh (E-mail: ntanhung@hueuni.edu.vn)

<b>Section</b>	<b>Content</b>	<b>Page</b>
<b>1</b>	<b>EXPERIMENTAL CHARACTERISATION .....</b>	3
1.1	Compound 1 .....	3
1.2	Compound 2 .....	11
1.3	Compound 3a .....	20
1.4	Compound 3b .....	27
1.5	Compound 3c .....	35
1.6	Compound 3d .....	43
1.7	Compound 3e .....	53
1.8	Compound 3f .....	61
1.9	Compound 3g .....	68
1.10	Compound 3h .....	76
1.11	Compound 3i .....	83
1.12	Compound 3k .....	90
1.13	Compound 3l .....	97
1.14	Compound 3m .....	104
1.15	Compound 4 .....	112
1.16	Compound 5 .....	137
1.17	Compound 6a .....	145
1.18	Compound 6b .....	154
1.19	Compound 6c .....	165
1.20	Compound 6d .....	175
1.21	Compound 6e .....	185
<b>2</b>	<b>COMPUTATIONAL SIMULATION .....</b>	194
2.1	In-detail data of ligand-3W37 inhibitory complexes .....	194
2.2	In-detail data of ligand-3AJ7 inhibitory complexes .....	197
2.3	In-detail data of ligand-PTP1B inhibitory complexes .....	200
<b>3</b>	<b>DOSE RESPONSE CURVE OF THE MOST POTENT COMPOUNDS.....</b>	203
3.1	Dose response curve of compound 5 .....	203
3.2	Dose response curve of compound 6c .....	204
3.3	Dose response curve of compound 6e .....	205


## 1. EXPERIMENTAL CHARACTERISATION

### 1.1. Compound 1







<sup>1</sup>H-NMR spectrum of compound 1




<sup>1</sup>H-NMR spectrum of compound **1** (extension)



<sup>1</sup>H-NMR spectrum of compound **1** (extension)




<sup>13</sup>C-NMR spectrum of compound **1**



<sup>13</sup>C-NMR spectrum of compound 1 (extension)

DEPT90




DEPT135

CH&CH<sub>3</sub>


CH<sub>2</sub>

C13CPD




DEPT spectrum of compound 1


DEPT90



DEPT135





C13CPD




DEPT spectrum of compound 1 (extension)

## 1.2. Compound 2







<sup>1</sup>H-NMR spectrum of compound 2




<sup>1</sup>H-NMR spectrum of compound **2** (extension)




<sup>1</sup>H-NMR spectrum of compound 2 (extension)



<sup>13</sup>C-NMR spectrum of compound 2




$^{13}\text{C}$ -NMR spectrum of compound **2** (extension)



<sup>13</sup>C-NMR spectrum of compound 2 (extension)


DEPT90



DEPT135




C13CPD




DEPT spectrum of compound 2


DEPT90



DEPT135




C13CPD




DEPT spectrum of compound **2** (extension)

### 1.3. Compound 3a


Sample name: DNPyrzin  
Operator: Le Anh VHH  
Method: +IDA TOF MS/MS  
Date: 2021.04.23




(+)-HR-ESI-MS spectrum of compound 3a




<sup>1</sup>H-NMR spectrum of compound 3a




<sup>1</sup>H-NMR spectrum of compound **3a** (extension)




<sup>1</sup>H-NMR spectrum of compound 3a (extension)



<sup>13</sup>C-NMR spectrum of compound 3a



$^{13}\text{C}$ -NMR spectrum of compound **3a** (extension)



<sup>13</sup>C-NMR spectrum of compound 3a (extension)


## 1.4. Compound 3b

Sample name: DNcinnamic


Operator: Le Anh VHH

Method: +IDA TOF MS/MS


Date: 2021.04.23




(+)-HR-ESI-MS spectrum of compound 3b





(+)-ESI-MS spectrum of compound **3b**






<sup>1</sup>H-NMR spectrum of compound **3b** (extension)






<sup>13</sup>C-NMR spectrum of compound 3b



<sup>13</sup>C-NMR spectrum of compound **3b** (extension)

DNCynamic-CDCl<sub>3</sub>-C13CPD


BRUKER



<sup>13</sup>C-NMR spectrum of compound **3b** (extension)

## 1.5. Compound 3c


Sample name: DNBenzolic  
Operator: Le Anh VHH  
Method: +IDA TOF MS/MS  
Date: 2021.04.23




---


Device Model: SCIEX X500 QTOF

(+)-HR-ESI-MS spectrum of compound 3c







<sup>1</sup>H-NMR spectrum of compound 3c




<sup>1</sup>H-NMR spectrum of compound 3c (extension)




<sup>1</sup>H-NMR spectrum of compound 3c (extension)



<sup>13</sup>C-NMR spectrum of compound 3c



<sup>13</sup>C-NMR spectrum of compound 3c (extension)



<sup>13</sup>C-NMR spectrum of compound 3c (extension)


## 1.6. Compound 3d

Sample name: DNII


Operator: Le Anh VHH


Method: +IDA TOF MS/MS


Date: 2021.04.23



(+)-HR-ESI-MS spectrum of compound 3d










<sup>1</sup>H-NMR spectrum of compound 3d


DNII-CDC13-1H




<sup>1</sup>H-NMR spectrum of compound **3d** (extension)




<sup>1</sup>H-NMR spectrum of compound **3d** (extension)




<sup>1</sup>H-NMR spectrum of compound **3d** (extension)



<sup>13</sup>C-NMR spectrum of compound **3d**



$^{13}\text{C}$ -NMR spectrum of compound **3d** (extension)



<sup>13</sup>C-NMR spectrum of compound 3d (extension)


### 1.7. Compound 3e

Sample name: DNNicotinic


Operator: Le Anh VHH


Method: +IDA TOF MS/MS

Date: 2021.04.23




(+)-HR-ESI-MS spectrum of compound 3e







<sup>1</sup>H-NMR spectrum of compound 3e




<sup>1</sup>H-NMR spectrum of compound 3e (extension)




<sup>1</sup>H-NMR spectrum of compound 3e (extension)



$^{13}\text{C}$ -NMR spectrum of compound **3e**




<sup>13</sup>C-NMR spectrum of compound 3e (extension)



<sup>13</sup>C-NMR spectrum of compound 3e (extension)


### 1.8. Compound 3f

**Sample name:** DN4Cl<sub>a</sub>  
**Operator:** Le Anh VH  
**Method:** -IDA TOF MS/MS  
**Date:** 2021.04.23




Hit	Formula	$m/z$	RDB ppm	MS Rank	MSMS ppm	MSMS Rank	Found
1	C <sub>37</sub> H <sub>54</sub> CINO <sub>3</sub>	630.34862	10.0	-1.2	1		NA/NA


(-) -HR-ESI-MS spectrum of compound 3f




$^1\text{H}$ -NMR spectrum of compound **3f**




<sup>1</sup>H-NMR spectrum of compound 3f (extension)




<sup>1</sup>H-NMR spectrum of compound 3f (extension)



$^{13}\text{C}$ -NMR spectrum of compound **3f**




<sup>13</sup>C-NMR spectrum of compound 3f (extension)




<sup>13</sup>C-NMR spectrum of compound 3f (extension)


### 1.9. Compound 3g

**Sample name:** DN4F  
**Operator:** Le Anh VHH  
**Method:** +IDA TOF MS/MS  
**Date:** 2021.04.23




(+)-HR-ESI-MS spectrum of compound 3g







<sup>1</sup>H-NMR spectrum of compound 3g




<sup>1</sup>H-NMR spectrum of compound 3g (extension)




<sup>1</sup>H-NMR spectrum of compound 3g (extension)



$^{13}\text{C}$ -NMR spectrum of compound **3g**




<sup>13</sup>C-NMR spectrum of compound 3g (extension)




<sup>13</sup>C-NMR spectrum of compound 3g (extension)

### 1.10. Compound 3h


**Sample name:** DNOla  
**Operator:** Le Anh VHH  
**Method:** +IDA TOF MS/MS  
**Date:** 2021.04.23




(+)-HR-ESI-MS spectrum of compound **3h**




<sup>1</sup>H-NMR spectrum of compound 3h




<sup>1</sup>H-NMR spectrum of compound **3h** (extension)




<sup>1</sup>H-NMR spectrum of compound **3h** (extension)



<sup>13</sup>C-NMR spectrum of compound **3h**




<sup>13</sup>C-NMR spectrum of compound **3h** (extension)




<sup>13</sup>C-NMR spectrum of compound **3h** (extension)

### 1.11. Compound **3i**




(+)-HR-ESI-MS spectrum of compound 3i




<sup>1</sup>H-NMR spectrum of compound 3i


**DN3F-CDC13-1H**




<sup>1</sup>H-NMR spectrum of compound **3i** (extension)




<sup>1</sup>H-NMR spectrum of compound 3i (extension)



<sup>13</sup>C-NMR spectrum of compound **3i**




$^{13}\text{C}$ -NMR spectrum of compound **3i** (extension)



<sup>13</sup>C-NMR spectrum of compound 3i (extension)


### 1.12. Compound 3k

**Sample name:** DNAca  
**Operator:** Le Anh VHH  
**Method:** +IDA TOF MS/MS  
**Date:** 2021.04.23



(+)-HR-ESI-MS spectrum of compound **3k**

**DHAc-CDC13-1H**




<sup>1</sup>H-NMR spectrum of compound **3k**

Current Data Parameters  
 NAME 1LOC\_DHAc  
 EXPNO 10  
 PROCNO 1


F2 - Acquisition Parameters  
 Date\_ 20181017  
 Time 11.32  
 INSTRUM spect  
 PROBHD 5 mm PABBO BB/  
 PULPROG zg30  
 TD 65536  
 SOLVENT CDC13  
 NS 16  
 DS 2  
 SWH 10000.000 Hz  
 FIDRES 0.1523888 Hz  
 AQ 3.2767999 sec  
 RG 30.85  
 DW 50.000 usec  
 DE 6.50 usec  
 TE 303.2 K  
 D1 1.0000000 sec  
 TDO 1  
 ===== CHANNEL f1 =====  
 SFO1 500.2030889 MHz  
 NUC1 <sup>1</sup>H  
 P1 10.00 usec  
 PLW1 22.0000000 W  
 F2 - Processing parameters  
 SI 65536  
 SF 500.2000055 MHz  
 WDW EM  
 SSB 0  
 LB 0.30 Hz  
 GB 0  
 PC 1.00

DHAc-CDCl<sub>3</sub>-1H




<sup>1</sup>H-NMR spectrum of compound **3k** (extension)


DHAc-CDCl<sub>3</sub>-1H




<sup>1</sup>H-NMR spectrum of compound 3k (extension)



<sup>13</sup>C-NMR spectrum of compound **3k**



$^{13}\text{C}$ -NMR spectrum of compound **3k** (extension)



<sup>13</sup>C-NMR spectrum of compound **3k** (extension)


### 1.13. Compound 3l

**Sample name:** DHV2a

**Operator:** Le Anh VHH


**Method:** +IDA TOF MS/MS

**Date:** 2021.04.23




Hit	Formula	m/z	RDB	ppm	MS Rank	MSMS ppm	MSMS Rank	Found
1	C <sub>35</sub> H <sub>59</sub> NO <sub>3</sub>	542.45677	7.0	3.7	1			NA/NA

(+)-HR-ESI-MS spectrum of compound 3l




<sup>1</sup>H-NMR spectrum of compound 3l

DHV2-CDCl<sub>3</sub>-1H




<sup>1</sup>H-NMR spectrum of compound **3l** (extension)

DHV2-CDC13-1H



<sup>1</sup>H-NMR spectrum of compound **3I** (extension)

DHV2-CDC13-C13CPD



<sup>13</sup>C-NMR spectrum of compound 3l



Current Data Parameters  
NAME ILOC\_DHV2  
EXPNO 2  
PROCNO 1


F2 - Acquisition Parameters  
Date\_ 20181026  
Time 16.41  
INSTRUM spect  
PROBHD 5 mm PABBO BB/  
PULPROG zgppg30  
TD 65536  
SOLVENT CDCl3  
NS 128  
DS 4  
SWH 31250.000 Hz  
FIDRES 0.476837 Hz  
AQ 1.0485760 sec  
RG 198.57  
DW 16.000 usec  
DE 6.50 usec  
TE 304.1 K  
D1 2.0000000 sec  
D11 0.03000000 sec  
TDO 1

===== CHANNEL f1 =====  
SFO1 125.7892253 MHz  
NUC1 <sup>13</sup>C  
P1 10.00 usec  
PLW1 88.00000000 W


===== CHANNEL f2 =====  
SFO2 500.2020008 MHz  
NUC2 <sup>1</sup>H  
CPDPRG[2] waltz16  
PCPD2 80.00 usec  
PLW2 22.00000000 W  
PLW12 0.34375000 W  
PLW13 0.22000000 W

F2 - Processing parameters  
SI 32768  
SF 125.7753900 MHz  
WDW EM  
SSB 0  
LB 1.00 Hz  
GB 0  
PC 1.40

DHV2-CDC13-C13CPD



<sup>13</sup>C-NMR spectrum of compound **3l** (extension)



$^{13}\text{C}$ -NMR spectrum of compound **3I** (extension)


## 1.14. Compound 3m

Sample name: DNOIZb

Operator: Le Anh VHH


Method: +IDA TOF MS/MS

Date: 2021.04.23




Hit	Formula	m/z	RDB	ppm	MS Rank	MSMS ppm	MSMS Rank	Found
1	C <sub>34</sub> H <sub>57</sub> NO <sub>3</sub>	550.43307	7.0	4.8	1			NA/NA


(+)-HR-ESI-MS spectrum of compound 3m




(+)-ESI-MS spectrum of compound 3m




<sup>1</sup>H NMR spectrum of compound 3m




<sup>1</sup>H NMR spectrum of compound **3m** (extension)




<sup>1</sup>H NMR spectrum of compound 3m (extension)



<sup>13</sup>C-NMR spectrum of compound **3m**




<sup>13</sup>C-NMR spectrum of compound **3m** (extension)




<sup>13</sup>C-NMR spectrum of compound **3m** (extention)

## 1.15. Compound 4


Sample name: DipG2  
Operator: Le Anh VHH  
Method: +IDA TOF MS/MS  
Date: 2021.04.23




(+)-HR-ESI-MS spectrum of compound 4




(+)-ESI-MS spectrum of compound 4




<sup>1</sup>H-NMR spectrum of compound 4




<sup>1</sup>H-NMR spectrum of compound **4** (extension)




<sup>1</sup>H-NMR spectrum of compound **4** (extension)




<sup>1</sup>H-NMR spectrum of compound 4 (extension)



<sup>13</sup>C-NMR spectrum of compound 4




<sup>13</sup>C-NMR spectrum of compound **4** (extension)



<sup>13</sup>C-NMR spectrum of compound 4 (extension)

DEPT90




DEPT135

CH&CH<sub>3</sub>


CH<sub>2</sub>

C13CPD




DEPT spectrum of compound 4


DEPT90




DEPT135




C13CPD




DEPT spectrum of compound 4 (extension)




COSY spectrum of compound 4




COSY spectrum of compound 4 (extension)




COSY spectrum of compound 4 (extension)




COSY spectrum of compound 4 (extension)




HSQC spectrum of compound 4




HSQC spectrum of compound 4 (extension)




HMBC spectrum of compound 4




HMBC spectrum of compound 4 (extension)




HMBC spectrum of compound 4 (extension)




HMBC spectrum of compound 4 (extension)




HMBC spectrum of compound 4 (extension)



NOESY spectrum of compound 4




NOESY spectrum of compound 4 (extension)




NOESY spectrum of compound 4 (extension)

## 1.16. Compound 5


Sample name: DipOH  
Operator: Le Anh VHH  
Method: +IDA TOF MS/MS  
Date: 2021.04.23




(+)-HR-ESI-MS spectrum of compound 5




<sup>1</sup>H-NMR spectrum of compound 5




<sup>1</sup>H-NMR spectrum of compound **5** (extension)



<sup>1</sup>H-NMR spectrum of compound **5** (extension)




<sup>13</sup>C-NMR spectrum of compound **5**



<sup>13</sup>C-NMR spectrum of compound 5 (extension)


DEPT90



DEPT135




C13CPD



DEPT spectrum of compound 5


DEPT90



DEPT135




C13 CPD



DEPT spectrum of compound 5 (extension)


### 1.17. Compound 6a

**Sample name:** DIPAcE  
**Operator:** Le Anh VHH  
**Method:** +IDA TOF MS/MS  
**Date:** 2021.04.23




Hit	Formula	$m/z$	RDB	ppm	MS Rank	MSMS ppm	MSMS Rank	Found
1	C <sub>29</sub> H <sub>46</sub> O <sub>4</sub>	481.32883	7.0	4.3	1			NA/NA


(+)-HR-ESI-MS spectrum of compound **6a**




(+)-ESI-MS spectrum of compound **6a**




<sup>1</sup>H-NMR spectrum of compound 6a




<sup>1</sup>H-NMR spectrum of compound **6a** (extension)



<sup>1</sup>H-NMR spectrum of compound **6a** (extension)




<sup>13</sup>C-NMR spectrum of compound **6a**



<sup>13</sup>C-NMR spectrum of compound **6a** (extension)

DEPT90



DEPT135


CH&CH<sub>3</sub>

CH<sub>2</sub>


C13CPD

DEPT spectrum of compound **6a**


DEPT90



DEPT135




C13CPD



DEPT spectrum of compound **6a** (extension)


### 1.18. Compound 6b


**Sample name:** DipVali  
**Operator:** Le Anh VHH  
**Method:** +IDA TOF MS/MS  
**Date:** 2021.04.23




Hit	Formula	$m/z$	RDB	ppm	MS Rank	MSMS ppm	MSMS Rank	Found
1	C <sub>32</sub> H <sub>52</sub> O <sub>4</sub>	523.3858	7.0	3.6	1			NA/NA

(+)-HR-ESI-MS spectrum of compound **6b**







<sup>1</sup>H-NMR spectrum of compound 6b




<sup>1</sup>H-NMR spectrum of compound **6b** (extension)




<sup>1</sup>H-NMR spectrum of compound **6b** (extension)



<sup>13</sup>C-NMR spectrum of compound **6b**




<sup>13</sup>C-NMR spectrum of compound **6b** (extension)




<sup>13</sup>C-NMR spectrum of compound **6b** (extension)


DEPT90



DEPT135




C13CPD



DEPT spectrum of compound **6b**

DEPT90



DEPT135


CH&CH<sub>3</sub>

CH<sub>2</sub>


C13CPD

DEPT spectrum of compound **6b** (extension)


DEPT90



DEPT135




C13CPD




DEPT spectrum of compound **6b** (extension)


### 1.19. Compound 6c

**Sample name:** Diplzo  
**Operator:** Le Anh VHH  
**Method:** +IDA TOF MS/MS  
**Date:** 2021.04.23




(+)-HR-ESI-MS spectrum of compound **6c**







<sup>1</sup>H-NMR spectrum of compound **6c**




<sup>1</sup>H-NMR spectrum of compound **6c** (extension)




<sup>1</sup>H-NMR spectrum of compound **6c** (extension)



<sup>13</sup>C-NMR spectrum of compound **6c**




<sup>13</sup>C-NMR spectrum of compound **6c** (extension)



<sup>13</sup>C-NMR spectrum of compound **6c** (extension)

DEPT90




DEPT135

CH&CH<sub>3</sub>


CH<sub>2</sub>

C13CPD




DEPT spectrum of compound **6c**


DEPT90



DEPT135




C13CPD




DEPT spectrum of compound **6c** (extension)


## 1.20. Compound 6d

**Sample name:** DipSali  
**Operator:** Le Anh VHH  
**Method:** +IDA TOF MS/MS  
**Date:** 2021.04.23




(+)-HR-ESI-MS spectrum of compound **6d**







<sup>1</sup>H-NMR spectrum of compound 6d




<sup>1</sup>H-NMR spectrum of compound **6d** (extension)




<sup>1</sup>H-NMR spectrum of compound **6d** (extension)



<sup>13</sup>C-NMR spectrum of compound **6d**




<sup>13</sup>C-NMR spectrum of compound **6d** (extension)



<sup>13</sup>C-NMR spectrum of compound **6d** (extension)

DEPT90




DEPT135

CH&CH<sub>3</sub>


CH<sub>2</sub>

C13CPD




DEPT spectrum of compound **6d**


DEPT90



DEPT135




C13CPD




DEPT spectrum of compound **6d** (extension)

### 1.21. Compound 6e


**Sample name:** DipCima  
**Operator:** Le Anh VHH  
**Method:** +IDA TOF MS/MS  
**Date:** 2021.04.23




(+)-HR-ESI-MS spectrum of compound **6e**




<sup>1</sup>H-NMR spectrum of compound 6e




<sup>1</sup>H-NMR spectrum of compound **6e** (extension)




<sup>1</sup>H-NMR spectrum of compound **6e** (extension)



<sup>13</sup>C-NMR spectrum of compound **6e**




<sup>13</sup>C-NMR spectrum of compound **6e** (extension)




<sup>13</sup>C-NMR spectrum of compound **6e** (extension)


DEPT90



DEPT135




C13CPD




DEPT spectrum of compound **6e**


DEPT90



DEPT135



C13CPD



DEPT spectrum of compound **6e** (extension)

## 2. COMPUTATIONAL SIMULATION

### 2.1. In-detail data of ligand-3W37 inhibitory complexes

**Table S1.** Molecular docking simulation results for inhibitory complexes between the compounds and the protein 3W37 with amino acids: 1-3W37, 2-3W37, 3a-3W37, 3b-3W37, 3c-3W37, 3d-3W37, 3e-3W37, 3f-3W37, 3g-3W37, 3h-3W37, 3i-3W37, 3k-3W37, 3l-3W37, 3m-3W37, 4-3W37, 5-3W37, 6a-3W37, 6b-3W37, 6c-3W37, 6d-3W37, 6e-3W37

Ligand-protein complex			Hydrogen bond					van de Waals interaction	
Name	DS	RMSD	L	P	T	D	E		
1-3W37	-10.9	1.24	O	O	Asp666	H-donor	2.93	-0.8	Arg670, Arg699, Glu792, Ile759, Gly791, Tyr659, Thr790, Val760, Leu663, Asn758, Arg676, Ile672, Glu302, Met302
			O	O	Thr299	H-acceptor	2.94	-1.4	
2-3W37	-12.9	1.67	O	O	Thr681	H-donor	3.04	-0.7	Thr299, Arg670, Arg699, Phe680, Glu301
			N	O	Glu792	H-donor	2.89	-7.1	
			O	N	Arg814	H-acceptor	2.94	-3.2	
			O	N	Arg814	H-acceptor	3.22	-2.2	
3a-3W37	-9.7	1.89	C	O	Ile759	H-donor	3.00	-1.0	Glu301, Ile672, Arg676, Gly791, Thr790, Val760, Pro658, Leu663, Tyr659, Glu792, Thr662, Leu663, Arg699, Asp666, Arg670, Thr681, Phe680
			N	N	Ala761	H-acceptor	2.94	-3.5	
3b-3W37	-13.4	1.78	N	N	Arg670	H-acceptor	3.10	-0.9	Glu301, Ile672, Tyr659, Ile759, Leu663, Gly791, Thr662, Arg676, Asp666, Arg699, Asp684, Phe682, Thr681
			O	N	Arg670	H-acceptor	3.02	-2.2	
			6-ring	C	Glu792	π-H	4.16	-0.9	
3c-3W37	-10.6	1.29	C	O	Asp666	H-donor	3.16	-0.7	Leu663, Arg670, Gly791, Glu792, Tyr659, Thr662, Thr790, Thr681, Phe680, Arg814, Glu301
			O	N	Arg699	H-acceptor	2.94	-1.2	
3d-3W37	-12.3	1.29	N	N	Arg670	H-acceptor	3.10	-0.8	Thr790, Gly791, Thr681, Glu301, Phe680, Pro683, Asp684, Asp666, Leu663, Ile672, Thr662, Tyr659, Glu792
			O	N	Arg670	H-acceptor	3.13	-1.2	
			O	N	Arg676	H-acceptor	3.52	-0.7	
			O	N	Arg699	ionic	3.41	-2.3	
3e-3W37	-13.8	1.12	O	S	Met302	H-donor	3.86	-1.1	Asp305, Glu792, Thr790, Arg670, Asn758, Gly700, Tyr659, Leu663, Asp666, Arg814, Glu301
			O	C	Gly791	H-acceptor	3.19	-0.7	
			N	C	Arg699	H-acceptor	3.65	-0.6	
			O	N	Arg699	ionic	3.41	-2.3	

			N	N	Arg699	ionic	3.21	-3.2	
			N	N	Arg699	ionic	3.13	-3.7	
3f-3W37	-10.5	1.94	N	N	Arg699	H-acceptor	2.91	-2.4	Pro683, Arg670, Glu301, Phe680, Asp666, Thr790, Val760, Ile754, Gly791, Ile701, Ile759, Gly700, Gly698, Thr681, Glu792, Arg814, Met302, Thr299
			6-ring	C	Tyr659	$\pi$ -H	3.69	-0.6	
3g-3W37	-9.8	2.05	C	O	Asp666	H-donor	3.10	-1.0	Pro683, Leu663, Thr790, Glu792, Arg670, Tyr659, Thr662, Gly791, Thr681, Phe680, Glu301, Thr299, Arg298
			O	N	Arg699	H-acceptor	2.99	-1.2	
3h-3W37	-9.9	1.92	O	O	Asp666	H-donor	2.91	-1.2	Asp684, Glu301, Arg676, Arg699, Tyr659, Gly698, Leu663, Ile759, Val760, Thr790, Gly791, Glu792, Arg670, Thr299, Pro683
			O	N	Arg298	H-acceptor	2.98	-1.5	
3i-3W37	-11.3	1.81	N	N	Arg699	H-acceptor	3.28	-1.6	Met302, Phe680, Thr299, Glu301, Thr681, Gly791, Glu792, Tyr659, Leu663, Asp666, Ile672, Pro683, Arg298
			O	N	Arg670	H-acceptor	3.25	-0.7	
			O	N	Arg676	H-acceptor	3.21	-1.0	
			O	N	Arg676	H-acceptor	3.35	-1.2	
3k-3W37	-11.6	1.03	O	O	Thr681	H-donor	3.04	-0.8	Asp684, Pro683, Phe680, Ile672, Glu301, Arg676, Asp666, Thr790, Arg814, Gly791, Arg670, Glu792
			N	N	Arg699	H-acceptor	2.86	-1.0	
			O	N	Arg699	H-acceptor	3.64	-0.5	
3l-3W37	-10.9	1.70	O	O	Asp666	H-donor	2.96	-1.2	Arg298, Gly700, Asn758, Val760, Thr790, Tyr659, Arg699, Ile759, Gly791, Arg676, Glu792, Ile672, Glu301, Pro683, Thr299
			O	N	Arg670	H-acceptor	2.73	-0.7	
3m-3W37	-9.1	1.95	O	N	Arg699	H-acceptor	3.19	-2.3	Val760, Leu663, Gly698, Tyr659, Glu792, Thr790, Arg670, Arg676, Asp666, Pro683, Thr299, Ile759, Gly791, Asn758
4-3W37	-8.5	1.87	O	N	Arg699	H-acceptor	3.11	-1.6	Thr790, Arg670, Thr299, Met302, Arg814, Glu792, Gly791
5-3W37	-14.9	1.30	O	N	Arg670	H-acceptor	2.96	-0.9	Met302, Thr299, Gly698, Glu792, Asp666, Leu663, Arg699, Ile672, Glu301
			O	N	Arg676	H-acceptor	2.86	-4.4	
			O	N	Arg676	H-acceptor	3.22	-0.8	
6a-3W37	-9.7	1.19	O	N	Arg676	H-acceptor	2.83	-4.6	Glu792, Gly791, Asp666, Leu663, Ile759, Asn758, Thr662, Val760, Gly700, Gly698, Tyr659, Thr790, Arg670, Arg676.
6b-3W37	-10.1	1.22	O	N	Arg699	H-acceptor	2.99	-0.8	Arg670, Arg676, Glu792, Leu663, Asn758, Gly698, Val760, Gly791, Tyr659, Ile701, Ile759, Thr790, Asp666, Arg814
			O	N	Gly700	H-acceptor	2.82	-2.8	
6c-3W37	-13.2	1.12	O	O	Asn758	H-donor	2.60	-1.2	Ile759, Glu792, Tyr659, Thr662, Asp666, Leu663, Arg676, Ile672, Arg670, Val760, Gly698, Gly791, Thr790, Gly700
			O	N	Arg699	H-acceptor	2.96	-1.6	
6d-3W37	-13.7	1.31	C	O	Asp666	H-donor	3.33	-0.8	Gly698, Ile759, Leu663, Asn758, Gly791, Thr662, Tyr659, Thr790, Arg670

			O	N	Arg676	H-acceptor	3.25	-1.7	
			O	N	Arg676	H-acceptor	3.35	-0.7	
			6-ring	C	Glu792	$\pi$ -H	4.34	-0.7	
			O	N	Lý309	H-acceptor	3.42	-1.5	
			O	N	Arg670	H-acceptor	3.12	-2.1	
			O	N	Arg676	H-acceptor	3.37	-0.6	
			6-ring	C	Glu792	$\pi$ -H	4.36	-0.6	
<b>6e-3W37</b>	-15.2	0.31							Arg699, Ile759, Tyr659, Thr662, Gly791, Leu663, Ile672, Asp666, Glu301, Asp305, Met302
<b>DS:</b> Docking score energy (kcal.mol <sup>-1</sup> ); <b>RMSD:</b> Root-mean-square deviation (Å); <b>L:</b> Ligand; <b>P:</b> Protein; <b>T:</b> Type; <b>D:</b> Distance (Å); <b>E:</b> Energy (kcal.mol <sup>-1</sup> )									

## 2.2. In-detail data of ligand-3AJ7 inhibitory complexes

**Table S2.** Molecular docking simulation results for inhibitory complexes between the compounds and the protein 3AJ7 with amino acids: **1-3AJ7, 2-3AJ7, 3a-3AJ7, 3b-3AJ7, 3c-3AJ7, 3d-3AJ7, 3e-3AJ7, 3f-3AJ7, 3g-3AJ7, 3h-3AJ7, 3i-3AJ7, 3k-3AJ7, 3l-3AJ7, 3m-3AJ7, 4-3AJ7, 5-3AJ7, 6a-3AJ7, 6b-3AJ7, 6c-3AJ7, 6d-3AJ7, 6e-3AJ7**

Ligand-protein complex			Hydrogen bond					van der Waals interaction	
Name	DS	RMSD	L	P	T	D	E		
<b>1-3AJ7</b>	-10.2	1.59	O	O	Pro312	H-donor	2.77	-2.3	Phe178, Glu411, Phe159, Gln279, Arg315, Asp242, His280, Leu313, Phe303, Ser311, Phe314, Asp307, Tyr158, Glu277, Asp252
			O	N	Arg442	H-acceptor	3.29	-2.0	
<b>2-3AJ7</b>	-11.9	1.46	O	O	Asp242	H-donor	2.76	-3.3	Asp69, Asp307, Glu277, His280, Phe303, Ser240, Phe178, Val216, Tyr158, Ser241, Gln279, Lys156, Pro312, Ser157, Arg315, Phe159, Glu411, Asp242
			O	N	Arg442	H-acceptor	2.75	-1.3	
<b>3a-3AJ7</b>	-9.5	1.77	O	O	Asp242	H-donor	2.63	-1.2	His280, Leu246, Tyr158, Asp69, Asp352, Asp215, Tyr72, Arg442, Phe178, Glu411, Phe303, Arg315, Phe159, Gln279, Pro312, Leu313, Asp307, Ph314
			C	O	Glu277	H-donor	3.05	-0.9	
			O	O	Ser240	H-acceptor	2.79	-1.5	
<b>3b-3AJ7</b>	-12.2	0.99	C	O	Glu277	H-donor	3.42	-0.7	Leu313, Pro312, Gln279, Tyr316, Phe314, His280, Phe303, Glu411, Arg315, Phe178, Tyr158, Asp307, Phe159, Asp215, Asp69, Asp352, Gln353, Arg442, Asp242, Val232
			C	O	Ser240	H-acceptor	2.68	-1.5	
			C	6-ring	Tyr72	H-π	4.09	-0.6	
<b>3c-3AJ7</b>	-11.8	1.45	O	O	Pro312	H-donor	2.64	-1.9	Asp242, Tyr158, Ser240, Lys156, Phe303, Ser241, Tyr72, Ser157, His112, Arg442, Glu277, Asp215, Asp352, Gln182, Arg446, Val216, Gln352, Asp69, Asp307, Glu411, Gln279, Arg315, His280, Leu313, Phe314
			O	N	His351	H-acceptor	3.14	-1.1	
			6-ring	6-ring	Phe178	π-π	3.96	-0.0	
<b>3d-3AJ7</b>	-10.9	1.43	O	O	Asp352	H-donor	3.03	-0.8	Tyr72, His112, Asp215, Tyr158, Glu277, Phe303, Phe178, Gln279, Asp307, Val216, Asp242, Pro312, Val232, Leu313, Phe314, Arg315, Glu411, Gln353, Arg442, Asp69
			N	O	Ser240	H-acceptor	3.07	-1.1	
			O	O	Ser240	H-acceptor	2.77	-1.8	
<b>3e-3AJ7</b>	-15.3	1.79	O	O	Asp242	H-donor	2.61	-1.0	Phe314, Pro312, Ser311, Asp307, Leu313, Phe303, His280, Arg315, Gln279, Phe178, Glu411, Asp215, Phe159, Arg446, Asp69, His351, Asp352, Tyr72, Glu277, Val215, Tyr158, Val 232
			O	O	Ser240	H-acceptor	2.88	-0.6	
			O	N	Arg442	ionic	3.21	-3.2	
			N	N	Arg442	Ionic	2.79	-6.0	
			N	N	Arg442	ionic	4.00	-0.5	
<b>3f-3AJ7</b>	-12.2	1.37	O	O	Asp242	H-donor	2.62	-1.3	Leu246, Ser240, Asp69, Tyr72, His112, Phe159, Gln182, Arg442, Phe178,

			C	O	Glu277	H-donor	3.08	-1.0	Asp352, Phe303, Tyr158, Arg315, Glu411, Asp307, Gln279, Ser311, Phe314,
			C	O	Asp215	H-donor	3.30	-0.8	Pro312, Leu313, His280.
3g-3AJ7	-9.9	1.14	O	O	Asp242	H-donor	2.81	-2.6	Tyr72, His112, Val109, Val216, Tyr158, Phe178, Asp215, Phe303, Phe159,
			O	N	His351	H-acceptor	3.12	-1.1	Glu277, Glu411, Gln279, Asp307, His280, Pro312, Arg315, Arg442, Gln182, Gln352, Asp352, Arg446, Asp69
3h-3AJ7	-10.4	1.43	I	O	Glu277	H-donor	3.48	-0.2	Pro312, Ser311, Arg315, Glu411, Asp353, Arg442, Val216, Tyr158, Phe303,
			C	5-ring	His280	H- $\pi$	3.55	-0.9	Asp242, Gln279, Ser304, Asp307.
3i-3AJ7	-11.7	1.26	C	O	Glu277	H-donor	3.48	-0.8	Asp242, Leu313, Ser241, Lys166, Ser240, Ser157, Leu177, His280, Tyr158,
			C	O	Asp69	H-donor	3.58	-0.6	Glu411, Phe178, Phe159, Gln279, Arg442, Tyr72, His112. Asp352, Asp215, Val216, Phe303, Arg315, Phe314, Pro312
3k-3AJ7	-12.7	1.78	O	O	Asp242	H-donor	2.78	-3.1	Ser311, Thr310, Gln279, Pro312, Thr306, Asp307, Phe303, Arg315, Tyr347, Arg213, Glu277, Glu411, His280, Ser240
			C	O	Asp352	H-donor	3.20	-0.7	
			O	N	Asn350	H-acceptor	2.98	-3.1	
			O	N	Gln353	H-acceptor	2.91	-2.2	
			C	6-ring	Tyr158	H- $\pi$	4.54	-0.8	
3l-3AJ7	-9.6	1.83	C	6-ring	Tyr158	H- $\pi$	4.49	-0.7	Ser304, Asp307, Gly309, His280, Thr310, val308, Ser241, Asp242, Ser157, Lys156, Ser240, Leu313, Pro312, Phe314
3m-3AJ7	-10.3	1.79	C	O	Glu277	H-donor	3.15	-0.8	Asp242, Pro312, Gln279, Arg315, Asp307, Phe159, Phe178, Thr306, Phe303,
			O	N	Asn350	H-acceptor	2.78	-2.2	Phe301, Arg213, Tyr347, His351, Asp352, Tyr158, Arg442, Glu411, His280, Val232, Ser240, Leu313.
			O	N	Gln353	H-acceptor	3.03	-2.3	
4-3AJ7	-10.2	1.15	O	N	Arg442	H-acceptor	3.50		Gln353, Glu277, Arg315, Phe303, Thr245, Asp242, Ser240, Lys156, Ser157, Asp307, Gln279, Glu411, Asp352, His280
			O	N	Ser241	H-acceptor	2.87		
			C	6-ring	Tyr158	H- $\pi$			
5-3AJ7	-15.9	1.02	O	N	Gln353	H-acceptor	2.96	-1.2	Ser240, Asp352, Thr306, Asp307, Phe303, Glu411, Arg442, Arg315, Pro312, Ser157, tyr316, Lys156, Asp242.
			O	N	Ser241	H-acceptor	3.04	-0.9	
			C	6-ring	Tyr158	H- $\pi$	3.96	-0.7	
			C	6-ring	Tyr158	H- $\pi$	4.35	-0.7	
6a-3AJ7	-11.6	1.67	O	N	Ser241	H-acceptor	2.99	-2.7	Val216, Asp352, Arg442, Phe314, glu411, Arg315, Ser240, Gln239, Asp242,
			C	6-ring	Tyr158	H- $\pi$	4.16	-0.6	Lys156, Asp307, Ser157, Phe159, Phe303, Gln279, His280, Phe178, Glu277,
			C	6-ring	Tyr158	H- $\pi$	4.22	-0.6	Asp216, Val216

<b>6b-3AJ7</b>	-10.6	1.22	C	O	Glu277	H-donor	3.39	-0.7	Tyr72, Asp352, Gln253, Arg442, Asp242, Pro312, Ser240, Val232, leu313, Asp233, His280, Gln279, Phe303, Glu411, Arg315, Tyr158, Asp215, Phe178, Val216, Arg213,
			O	N	His351	H-acceptor	3.25	-2.1	
<b>6c-3AJ7</b>	-13.7	0.97	O	C	Phe314	H-acceptor	3.30	-0.7	Gln353, Asp69, Asp352, Gln182, His351, tyr72, His112, Glu277, Gln279, Asp215, Phe178, Phe159, His280, Val216, Glu411, Phe303, Tyr158, Leu313, Pro312, Asp307, Ser311
			O	N	Arg315	H-acceptor	3.14	-1.6	
			O	N	Arg442	H-acceptor	2.91	-1.9	
<b>6d-3AJ7</b>	-12.5	0.95	O	O	Glu277	H-donor	2.70	-6.1	Asp242, Leu313, Pro312, Asp352, Asp69, Val216, Tyr72, Asp215, Phe178, Tyr158, Glu411, Phe303, His280, Arg315, Gln279, Gln239, Asp233, Val232, Phe159, Trp238.
			O	N	Lys156	H-donor	3.16	-5.0	
			O	N	Ser240	H-acceptor	3.16	-0.8	
			O	N	Arg442	H-acceptor	3.07	-1.2	
<b>6e-3AJ7</b>	-14.4	1.79	O	N	Ser241	H-acceptor	3.33	-1.0	Ser240, Lys156, Phe314, Pro312, His280, Leu313, Asp325, Ala329, Ile329, Ile328, Glu332, Asp307, Ser311, Thr310, Ser157, Asp242
			C	6-ring	Tyr158	H- $\pi$	4.65	-0.6	
			6-ring	C	Ser304	$\pi$ -H	3.68	-0.7	

**DS:** Docking score energy (kcal.mol<sup>-1</sup>); **RMSD:** Root-mean-square deviation (Å); **L:** Ligand; **P:** Protein; **T:** Type; **D:** Distance (Å); **E:** Energy (kcal.mol<sup>-1</sup>)

### 2.3. In-detail data of ligand-PTP1B inhibitory complexes

**Table S3.** Molecular docking simulation results for inhibitory complexes between the compounds and the protein PTP1B with amino acids: **1-PTP1B**, **2-PTP1B**, **3a-PTP1B**, **3b-PTP1B**, **3c-PTP1B**, **3d-PTP1B**, **3e-PTP1B**, **3f-PTP1B**, **3g-PTP1B**, **3h-PTP1B**, **3i-PTP1B**, **3k-PTP1B**, **3l-PTP1B**, **3m-PTP1B**, **4-PTP1B**, **5-PTP1B**, **6a-PTP1B**, **6b-PTP1B**, **6c-PTP1B**, **6d-PTP1B**, **6e-PTP1B**

Ligand-protein complex			Hydrogen bond					van der Waals interaction	
Name	DS	RMSD	L	P	T	D	E		
<b>1-PTP1B</b>	-10.5	1.19	O	N	Gly259	H-acceptor	2.87	-1.8	Arg47, Asp29, Ser28, Met258, Gly259, Ala27, Arg254, Ser50, Arg24, Lys36
<b>2-PTP1B</b>	-13.8	1.17	O	N	Arg24	H-acceptor	3.41	-0.7	Lys36, Asp29, Arg254, Gly259, Met258, Asp48, Cys32
			O	N	Arg24	H-acceptor	2.98	-2.5	
			O	N	Gln262	H-acceptor	3.24	-1.6	
<b>3a-PTP1B</b>	-9.3	1.25	C	O	Phe30	H-acceptor	3.50	-0.7	Tyr46, Asp48, Arg24, Met258, Asp29, Pro31, Phe52, Lys36, Asp181, Lys120, Phe182
			N	N	Cys32	H-acceptor	3.22	-0.8	
<b>3b-PTP1B</b>	-11.5	1.98	O	O	Gln262	H-donor	3.16	-0.7	Tyr46, Asp48, Val49, Cys32, Phe30, Asp29, Arg24, Phe182, Ala217, Ile219
			6-ring	C	Pro31	$\pi$ -H	4.74	-0.6	
<b>3c-PTP1B</b>	-9.6	1.92	N	N	Arg24	H-acceptor	3.11	-2.0	Asp29, Met258, Tyr20, Gly259, Phe182, Arg254
			N	N	Gln262	H-acceptor	3.03	-1.4	
<b>3d-PTP1B</b>	-13.7	1.89	O	N	Arg24	H-acceptor	3.33	-0.9	Lys120, Tyr46, Val49, Asp48, Gly259, Lys116, Ser118
			O	N	Arg24	H-acceptor	2.88	-1.7	
			O	N	Gln262	H-acceptor	2.87	-1.5	
			O	N	Arg24	H-acceptor	3.31	-0.7	
			O	N	Arg254	H-acceptor	3.05	-7.2	
			O	N	Arg24	ionic	3.31	-1.3	
			O	N	Arg254	ionic	3.05	-2.5	
			6-ring	C	Met258	$\pi$ -H	4.74	-0.6	
<b>3e-PTP1B</b>	-12.9	1.43	O	N	Arg24	H-acceptor	3.29	-1.8	Met258, Gln262, Ile219, Gly250, Cys32, Asp29, Asp48, Val49
			O	N	Lys36	H-acceptor	3.12	-2.8	
			O	N	Lys36	ionic	3.12	-2.1	
			6-ring	C	Lys36	$\pi$ -H	3.55	-0.7	

<b>3f-PTP1B</b>	-10.1	1.75	O	N	Cys32	H-acceptor	3.14	-1.8	Pro31, Arg33, Lys36, Met258, Asp48, Val49, Ile219, Asp29
			O	N	Arg24	H-acceptor	3.11	-2.4	
			O	N	Gln262	H-acceptor	3.57	-0.6	
<b>3g-PTP1B</b>	-9.0	1.90	O	N	Lys36	H-acceptor	3.23	-3.9	Cys32, Asp29, Asp48, Ile219, Val49, Phe182, Met258, Gly259
			O	N	Arg24	H-acceptor	3.32	-0.9	
			O	N	Gln262	H-acceptor	3.20	-2.0	
<b>3h-PTP1B</b>	-9.4	1.36	I	S	Met258	H-donor	3.66	-0.7	Val49, Ile219, Asp48, Lys36, Asp29
			O	N	Arg24	H-acceptor	2.91	-2.8	
			O	N	Gln262	H-acceptor	3.07	-2.9	
<b>3i-PTP1B</b>	-10.3	1.14	N	N	Gln262	H-acceptor	3.41	-0.9	Phe30, Arg33, Pro31, Asp29, Lys36, Met258, Tyr20, Asp48, Cys32
			O	N	Arg24	H-acceptor	2.87	-2.0	
			O	N	Gln262	H-acceptor	2.85	-0.7	
<b>3k-PTP1B</b>	-9.7	1.35	O	O	Arg24	H-donor	3.26	-0.8	Asp29, Ser28, Arg254, His25, Ala27, Gln21, Met258,
			O	N	Lys36	H-acceptor	3.06	-3.8	
<b>3l-PTP1B</b>	-9.9	1.60	O	N	Lys36	H-acceptor	3.36	-0.9	Val49, Asp48, Gly259, Met258, Arg33, Cys32, Asp29, Ser28, Arg24, Ile219, Gln262
			O	N	Arg254	H-acceptor	3.37	-1.2	
<b>3m-PTP1B</b>	-9.3	1.34	C	6-ring	Tyr46	H- $\pi$	4.42	-0.6	Met258, Asp48, Gly259, Gln262, Val49, Phe182, Arg24, Ser28, Asp29
<b>4PTP1B</b>	-11.2	1.23	C	S	Met258	H-donor	3.89	-0.8	Phe30, Lys36, Asp29, Gly259, Asp48, Pro31
			O	N	Cys32	H-acceptor	3.04	-3.3	
			O	N	Arg24	H-acceptor	3.13	-1.8	
			O	N	Gln262	H-acceptor	3.08	-1.5	
<b>5-PTP1B</b>	-13.4	1.37	O	N	Arg24	H-acceptor	2.87	-1.9	Asp29, Ser28, Gly259, ZGln262, Tyr20, Met258, Asp48
			O	N	Arg254	H-acceptor	3.27	-1.1	
			O	N	Arg254	H-acceptor	3.05	-3.1	
			O	N	Lys36	H-acceptor	3.25	-1.0	
<b>6a-PTP1B</b>	-9.8	1.40	O	N	Arg254	H-acceptor	2.85	-2.0	Pro31, Arg33, Phe30, Lys36, Asp29, Met258, Gly259, Arg24
			O	N	Cys32	H-acceptor	3.13	-1.0	
<b>6b-PTP1B</b>	-11.5	1.85	C	S	Met258	H-donor	4.16	-0.7	Pro31, cys32, Lys36, Gly259, Arg254, tyr20, Asp48, Asp29, Phe30
			O	N	Arg24	H-acceptor	3.38	-0.9	
			O	N	Arg24	H-acceptor	3.18	-0.9	


			O	N	Gln262	H-acceptor	3.13	-1.0	
<b>6c-PTP1B</b>	-15.8	1.99	O	N	His25	H-acceptor	3.03	-2.0	Asp46, Ile219, Val49, Met258, Gly259, Asp29, Ala27, Arg254, Ser28
			O	N	Arg24	H-acceptor	2.96	-3.7	
			O	N	Gln62	H-acceptor	3.49	-0.7	
			C	5-ring	His25	H- $\pi$	4.30	-0.7	
<b>6d-PTP1B</b>	-10.7	1.70	O	O	Gln262	H-donor	3.08	-0.9	Asp29, Met258, Asp48, Phe182, Tyr20
			O	N	Arg24	H-acceptor	2.87	-1.8	
			O	N	Gln262	H-acceptor	3.07	-1.6	
<b>6e-PTP1B</b>	-12.2	1.54	C	O	Ser80	H-donor	3.29	-0.8	Val211, Gly209, Pro206, His208, Pro206, Leu204, Glu75, Lys73, Arg79, Ser203, Ser205
			O	N	Gln78	H-acceptor	2.83	-0.8	
			6-ring	C	Glu76	$\pi$ -H	3.85	-1.2	

**DS:** Docking score energy (kcal.mol<sup>-1</sup>); **RMSD:** Root-mean-square deviation (Å); **L:** Ligand; **P:** Protein; **T:** Type; **D:** Distance (Å); **E:** Energy (kcal.mol<sup>-1</sup>)

### 3. DOSE RESPONSE CURVE OF THE MOST POTENT COMPOUNDS

#### 3.1. Dose response curve of compound 5


Compound 5	Concentration ( $\mu\text{g/ml}$ )	128	32	8	2	0.5	0.125	0.03
	Inhibitory rate (0-1)	1	0.99	0.98	0.62	0.41	0.15	0.07



Dose response curve of compound 5.

### 3.2. Dose response curve of compound 6c


Compound 6c	Concentration ( $\mu\text{g/ml}$ )	256	64	16	4	1
	Inhibitory rate (0-1)	0.77	0.75	0.71	0.71	0.35



Dose response curve of compound 6c.

### 3.3. Dose response curve of compound 6e

Compound 6e	Concentration ( $\mu\text{g/ml}$ )	256	64	16	4
	Inhibitory rate (0-1)	0.93	0.72	0.62	0.5



Dose response curve of compound 6e.